Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Summit Therapeutics Inc. is a biopharmaceutical company focused on developing patient-friendly cancer therapies, primarily in oncology. Its core product, ivonescimab, is a bispecific antibody targeting PD-1 and VEGF, designed to improve cancer treatment outcomes. The company advances its pipeline through clinical trials and strategic licensing, aiming to become a leader in innovative, immuno-oncology medicines for global markets.
This description was generated via AI from an annual report. Updated about 1 year ago.